Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + irinotecan + bevacizumab
- Development stage
- Phase 4
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capecitabine + irinotecan + bevacizumab is a combination chemotherapy regimen used primarily for the treatment of metastatic colorectal cancer. Capecitabine is an oral prodrug of 5-fluorouracil, which inhibits DNA synthesis in rapidly dividing cells. Irinotecan is a topoisomerase I inhibitor that prevents DNA replication and transcription in cancer cells. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis and tumor blood supply. This triplet regimen has demonstrated efficacy as first-line therapy for metastatic colorectal cancer, with studies showing improved progression-free survival and overall survival compared to doublet regimens[1][2][6]. The combination may be associated with increased toxicity, requiring dose adjustments in certain patient populations[3][4].
- Brand names
- Xeloda (capecitabine)Camptosar (irinotecan)Avastin (bevacizumab)
- Other names
- capecitabine + irinotecan + bevacizumabCAPIRI-BEVXELIRI-BEVCIRB
02
Targets
Beyond the preview
Go deeper on capecitabine + irinotecan + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + irinotecan + bevacizumab.